Key Takeaways

  • Martin Shkreli bought the rights to Sparsentan from Bristol Myers Squibb for $2 million; today, the public company holding that drug is worth $6 billion.
  • Giant pharmaceutical companies routinely abandon viable molecules because their internal benchmarks prioritize massive, mass-market indications over focused clinical wins.
  • Repurposing drugs turns scientific discovery risk into regulatory and positioning execution: shift a molecule from a crowded indication to an untreated rare disease.
  • Shkreli generated alpha by manually reading scientific literature and patent filings to find valuable compounds that corporate business development teams ignored.

The $2 Million Arbitrage on Corporate Balance Sheets

Big companies are terrible capital allocators at the margins. When a corporation employs 80,000 people and generates tens of billions in revenue, an asset that can generate $100 million annually is a distraction. Internal committees quietly shelve promising compounds because the potential revenue does not move their corporate needle.

Shkreli spotted this structural flaw early in his career after working at Jim Cramer's hedge fund. He realized that the market for buying physical molecules contained far more inefficiency than trading public stocks.

“It was a really inefficient market,” Shkreli said. “Pfizer would sell you a drug for a million bucks that was worth a billion dollars. They didn't care.”

The sellers were not stupid; their incentives were simply misaligned. Pfizer and Bristol Myers Squibb develop candidates targeted at massive populations. If a molecule fails to beat existing generics in a crowded category, the project dies on a spreadsheet. To the executive running that business unit, selling the compound for $1 million to clear administrative overhead is a rational choice. To an outside operator, that same compound is an underpriced call option with years of completed preclinical safety data.

Repositioning Sparsentan for Untreated Patients

Turning an abandoned compound into enterprise value requires changing the question the drug is trying to answer. Shkreli demonstrated this with Sparsentan, a compound Bristol Myers Squibb originally developed for hypertension.

Hypertension is saturated. Doctors already have dozens of cheap, off-patent blood pressure medications. Selling another entrant into that category requires hundreds of millions of dollars in marketing and commercial sales teams, with low odds of meaningful commercial success. Shkreli called hypertension “a dead sleepy market that nobody really needs.”

Instead of chasing that crowded market, Shkreli redirected the molecule toward focal segmental glomerulosclerosis (FSGS), a rare kidney disease.

“We moved into a disease called FSGS, which is a disease that never had a drug approved for it,” Shkreli noted. “So you sort of try to angle it in a way that makes sense. And in that case the drug got FDA approved. 30,000 people who have focal segmental glomerulosclerosis and never had a drug before now have a drug.”

By narrowing the target patient base from millions of hypertension sufferers to 30,000 FSGS patients, the operational math flipped. The regulatory path cleared because the FDA urgently needed solutions for an untreated condition. Shkreli acquired the asset for $2 million. As he pointed out, “that same company is public today. It's worth 6 billion.”

The operational moat was not complex algorithms. It was manual labor: “Our biggest constraint was finding people to vet these assets. So I started small: reading papers, reading patents, going to universities and small drug companies and big drug companies, making relationships. It's called business development in our field.”

What to Do With This

Find a legacy enterprise in your target industry and map the internal projects they shelved over the last three years because the target market was under $50 million. Contact the product leads or corporate development teams who worked on those projects and make an asset purchase offer with an upfront payment and future revenue royalties. Re-launch that shelved software or IP directly into a narrow, underserved vertical that the corporate giant could never justify pursuing.